New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For MDT;COV;INTC;BSX;VRTX;JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | all recent news | >>
January 29, 2015
11:46 EDTJNJPharmacyclics confirms FDA approval of IMBRUVICA
Subscribe for More Information
10:51 EDTBSXOptions with decreasing implied volatility
Subscribe for More Information
10:50 EDTJNJFDA expands use of Imbruvica to rare form of cancer
The FDA expanded the approved use of Imbruvica for previously treated patients with Waldenström’s macroglobulinemia, a rare form of cancer that begins in the body’s immune system. The drug received a breakthrough therapy designation for this use. The product's new use is being approved more than two months ahead of its prescription drug user fee goal date of April 17, the date the FDA was scheduled to complete review of the drug application. Imbruvica is co-marketed by Pharmacyclics (PCYC) and Johnson & Johnson's (JNJ) Janssen Biotech unit.
10:00 EDTVRTXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:16 EDTVRTXVertex downgraded at Maxim
Subscribe for More Information
09:07 EDTVRTXHead researchers of Vertex, Regeneron, Merck invited to White House, CNBC says
Subscribe for More Information
08:08 EDTVRTXVertex downgraded to Hold from Buy at Maxim
Subscribe for More Information
07:58 EDTJNJMedivation price target raised to $128 from $112 at Stifel
After surveying 25 urologists, Stifel believes that MEdivation's (MDVN) Xtandi drug has surpassed its main competitor, Johnson & Johnson's (JNJ) Zytiga, as a treatment of prostate cancer prior to chemotherapy. Stifel keeps a Buy rating on Medivation.
06:58 EDTVRTXVertex downgraded to Hold from Buy at Needham
Subscribe for More Information
January 28, 2015
18:21 EDTVRTXOn The Fly: After Hours Movers
Subscribe for More Information
16:07 EDTVRTXVertex sees FY15 KALYDECO net revenues $560M-$580M
FY15 revenue consensus $1.19B. KALYDECO net revenues reflect use of KALYDECO by eligible patients in Australia following the completion of reimbursement discussions in late 2014; use of KALYDECO in some people in the United States with the R117H mutation following FDA approval in late 2014; the completion of reimbursement discussions for gating mutations in certain European countries; and use of KALYDECO in children with CF ages 2 to 5 with the G551D or other gating mutations in the United States, based on potential approval in March 2015. Vertex expects that its combined non-GAAP R&D and SG&A expenses in 2015 will be in the range of $1.05B-$1.1B. The increase as compared to 2014 is primarily a result of launch preparation activities for lumacaftor in combination with ivacaftor and the planned pivotal Phase 3 development program for VX-661 in combination with ivacaftor.
16:05 EDTVRTXVertex reports Q4 adjusted EPS (55c), consensus (65c)
Reports Q4 revenue $145M, consensus $137.49M. Reports Q4 revenues of $124M from KALYDECO in CF.
15:37 EDTVRTXNotable companies reporting after market close
Subscribe for More Information
10:29 EDTBSXOptions with decreasing implied volatility
Subscribe for More Information
07:23 EDTINTCIntel pullback yesterday a buying opportunity, says Jefferies
Subscribe for More Information
05:58 EDTINTCIntel cooperates with Spreadtrum, Rockchip to enter China market, DigiTimes says
Intel (INTC) has cooperated with and Rockchip Electronics to rpomote its platforms in the China market, reports DigiTimes. According to Taiwan-based supply chain makers, the move is to compete with Qualcomm (QCOM) and Mediatek for smartphone and tablet use chip solutions. Intel is set to ship 44M tablet processors in 2015. Reference Link
05:48 EDTINTCStocks with implied volatility movement; INTC QQQ
Subscribe for More Information
January 27, 2015
13:43 EDTINTCIntel would not let AMD x86 license 'fall into hands' of China, Hesseldahl says
Following a Chinese language report claiming that Chinese company BLX IC Design could be interested in buying AMD (AMD), Re/code's Arik Hesseldahl said on Twitter that he believes there is "no way" Intel (INTC) would allow AMD's x86 license to fall into the hands of a China-based owner. AMD shares, which rose significantly yesterday, are up another 5.2% today in afternoon trading. Reference Link
13:16 EDTINTCAMD continues advance following Chinese report of takeover interest
Subscribe for More Information
11:29 EDTJNJBayer, Janssen form collaboration to study Xarelto in stroke patients
Subscribe for More Information
11:14 EDTINTCMicrosoft sinks after outlook brings multiple downgrades
Shares of Microsoft (MSFT) are falling after the company last night issued guidance for its quarter ending in March that came in significantly below analysts' expectations. JPMorgan, Citigroup, MKM Partners and Nomura responded to the company's results by downgrading the stock. BACKGROUND: Microsoft's revenue guidance for its March quarter missed expectations, driven by U.S. dollar strength, and continued weakness in China, Russia and Japan, according to JPMorgan analyst Mark Murphy. The company's second quarter results were roughly in-line with expectations, but its software sales came in below the consensus outlook, as customers shifted to cheaper Web-based products. ANALYST REACTION: In a note to investors, JPMorgan's Murphy downgraded the stock to Neutral for Overweight. Microsoft plans to spend more money than anticipated going forward, according to the analyst, who consequently cut his fiscal 2015 earnings per share forecast for the company by 8%. The reduced profit outlook could delay the stock's move above $50, warned Murphy, who reduced his price target on the name to $47 from $53. But the analyst did note that the tech giant’s commercial cloud revenue growth jumped 114% year-over-year last quarter, a higher growth rate than during the same period a year earlier. Citigroup cut its rating on Microsoft to Sell from Neutral, saying that the company's earnings headwinds are becoming clearer. The firm set a $38 price target on the stock. Both Nomura and MKM Partners cut its ratings on the name to Neutral from Buy. PRICE ACTION: In late morning trading, Microsoft fell 9.55 to $42.50. Other companies
10:14 EDTINTCIntel drops after Microsoft results, levels to watch
Shares are down 4.6% to $34.15 at time of writing as Microsoft's (MSFT) results weigh on PC-related shares. At current price, next support is at $33, a recent pivot low. Resistance is at $34.79.
08:42 EDTMDTMedtronic coverage resumed with a Buy at Goldman
Subscribe for More Information
January 26, 2015
17:06 EDTCOV, MDTMedtronic completes acquisition of Covidien for $49.9B
Subscribe for More Information
10:28 EDTINTCIntel trades down, testing lows of the recent range
Subscribe for More Information
08:54 EDTINTCIntel management to meet with Deutsche Bank
Subscribe for More Information
08:52 EDTBSX, JNJCourt ruling likely to be positive for Boston Scientific, says Bernstein
Subscribe for More Information
07:17 EDTMDT, COVSociety of Thoracic Surgeons to hold annual meeting
51st Annual Meeting of STS is being held in San Diego, California on January 24-28.
07:08 EDTMDT, COVMedtronic pending acquisition of Covidien approved by Irish High Court
Subscribe for More Information
January 23, 2015
16:55 EDTJNJMarket ends week higher after ECB announces bond purchase plan
Stocks finished higher for the week after the European Central Bank unveiled a larger than expected bond buying plan and earnings season in the U.S. picked up steam. MACRO NEWS: The European Central Bank announced that it would buy EUR 60B of government and private bonds per month through September 2016. Reports before the ECB's official announcement had suggested that the central bank would buy EUR 50B of bonds per month... On a negative note, the International Monetary Fund cut its 2015 global growth outlook to 3.5% from 3.8%... U.S. economic data was mixed, as weekly jobless claims and sales of existing homes in December were worse than expected, but the index of leading economic indicators and new housing permits for December came in above the consensus outlook. COMPANY NEWS: Netflix (NFLX), Starbucks (SBUX), firearm maker Smith & Wesson (SWHC), and Southwest Airlines (LUV) were among the companies whose stocks rose following their results and guidance. On the other side of the ledger, Johnson & Johnson (JNJ), IT management solution provider CA Technologies (CA), UPS (UPS), and application delivery networking products maker F5 Networks (FFIV) were among the companies that fell after they reported their earnings or updated their financial outlooks... M&A reports moved a number of stocks this week. The Financial Post reported that Samsung (SSNLF) had hired investment bank Evercore (EVR) to evaluate a purchase of the troubled Canadian company. Samsung is still considering purchasing BlackBerry (BBRY), the newspaper added. However, Canada's BNN reported that Evercore said that Samsung has not been a recent client of theirs and that they prepare ideas "routinely" on their "own accord." Avon (AVP) has held talks about a potential sale to private equity firm TPG Capital, dealReporter stated. Bloomberg reported that online travel agency Orbitz Worldwide (OWW) is working with an adviser to contact potential buyers and has drawn interest from private-equity funds and other Internet companies... DreamWorks Animation (DWA) tumbled after announcing a new strategic plan that will see it cut its feature production from three films per year down to two and axe about 500 jobs. INDEXES: For the week, the Dow dipped 0.37% to 17,672.60, the Nasdaq rose 1.14% to 4,757.88, and the S&P gained 0.34% to 2,051.82.
16:33 EDTMDTMedtronic reports 5.1% passive stake in Intersect ENT
Subscribe for More Information
15:46 EDTMDTPiper Jaffray's medtech analysts hold an analyst/industry conference call
Subscribe for More Information
14:02 EDTBSXJPMorgan reports 5.7% passive stake in Boston Scientific
08:36 EDTMDTMedtronic receives FDA approval for for the Medtronic Enterra II System
Subscribe for More Information
06:39 EDTJNJNIH, GlaxoSmithKline, Merck launch joint Ebola vaccine test in Liberia, WSJ says
Subscribe for More Information
06:04 EDTINTCIntel may look to form stylus alliance, DigiTimes reports
Intel has recently invited several touch sensor IC designers to form an alliance in order to establish a specification standard for stylus, reports DigiTimes. According to sources from IC designers, the alliance's first product is expected to launch in Q3 and will be to make the input device usable across different mobile devices. Reference Link
January 22, 2015
08:10 EDTCOVCovidien reports Q1 Medical Devices operational sales growth of 6%
Subscribe for More Information
08:08 EDTCOVCovidien reports Q1 adjusted EPS ms $1.11, consensus $1.05
Reports Q1 revenue $2.69B, consensus $2.72B. Operational sales growth in the quarter was 6%, as foreign exchange rate movement lowered the quarterly sales growth rate by four percentage points.
07:31 EDTJNJ, BSXBoston Scientific damages in case likely to be manageable, says Wells Fargo
Subscribe for More Information
05:47 EDTBSXStocks with implied volatility movement; BSX T
Stocks with implied volatility movement; Boston Scientific (BSX) 49, AT&T (T) 20 according to iVolatility.
January 21, 2015
18:27 EDTCOVOn The Fly: After Hours Movers
UP AFTER EARNINGS: eBay (EBAY), up 2.9%... United Rentals (URI), up 1.5%. ALSO HIGHER: Minerva (NERV), up 16.1% after reporting positive Phase 1 data with MIN-202... Endo (ENDP), up 3.1% after it was announced that Endo will replace Covidien in S&P 500 as of 1/26 close... Covidien (COV) is up 1%. DOWN AFTER EARNINGS: F5 Networks (FFIV), down 15.8%... Xilinx (XLNX), down 6.1%... Discover Financial Services (DFS), down 3.3%... American Express (AXP), down 2.2%. ALSO LOWER: BioMarin (BMRN), down 2.5% after filing to sell 7.25M shares of common stock... Kinder Morgan (KMI), down 1.9% after announcing that it will acquire Hiland Partners for approximately $3B and reporting fourth quarter results... Cisco (CSCO), down 1.4% after Bloomberg reported that Oracle's (ORCL) Ellison said that Oracle's new Virtual Compute Appliance is cheaper than Cisco's product.
18:06 EDTMDT, COVS&P announces changes to the S&P 500, MidCap 400, SmallCap 600 indices
Subscribe for More Information
17:18 EDTCOVEndo to replace Covidien in S&P 500 as of 1/26 close
16:35 EDTJNJMinerva reports positive Phase 1 data with MIN-202
Minerva Neurosciences (NERV) announced that preliminary results from a Phase 1 clinical study showed that treatment with MIN-202, a selective orexin-2 antagonist, resulted in significant improvements in sleep onset and sleep duration in patients with comorbid insomnia related to major depressive disorder, or MDD. Preliminary results from two additional Phase 1 studies also suggest that MIN-202 is well tolerated and possesses advantageous pharmacokinetic and pharmacodynamic features. The three Phase 1 studies were conducted by Janssen Research & Development, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ), as part of a collaboration to develop MIN-202 with Minerva that was facilitated by Johnson & Johnson Innovation Ltd in London.
15:27 EDTCOVNotable companies reporting before tomorrow's open
Subscribe for More Information
10:16 EDTJNJLeerink biopharma analysts hold an analyst/industry conference call
Analyst Fernandez, along with Dr. Paul Gurbel and Dr. Richard Becker, discuss AstraZeneca's PEGASUS trial and the current use of Brilinta and dual antiplatelet therapy for prevention of CV disease and implications of the recently completed DAPT trial on an Analyst/Industry conference call to be held on January 21 at 1:30 pm.
07:15 EDTINTCAny Intel server weakness likely a hiccup, says RBC Capital
After JMP Securities yesterday downgraded Intel (INTC) based partly on information from a source who said that server component sales have been weak in 2015, RBC Capital says any weakness is probably due to a three month delay caused by a technical problem and is not demand driven. RBC Capital expects the technical problem to be resolved within three months but keeps a $40 price target and Sector Perform rating on Intel.
January 20, 2015
16:23 EDTJNJOn The Fly: Closing Wrap
Stocks began the session in positive territory, but the major averages were unable to hold their early gains. Lackluster earnings reports, the falling price of oil, and lowered global growth expectations appeared to be too much to overcome after a three day holiday weekend. The Dow led the way lower and had losses of more than 100 points before reversing and slowly paring its losses. Late in the day the averages made it back to positive ground, as investors await the next round of earnings due out after the close. ECONOMIC EVENTS: In the U.S., the NAHB homebuilder sentiment index fell to 57 in January, missing expectations for it to hold steady at 58. In China, Q4 GDP growth of 7.3% came in slightly better than expected, though that puts the nation's 2014 GDP growth at 7.4%, which was the lowest reported in 24 years. Of note, the International Monetary Fund cut its forecast for global growth in 2015 to 3.5% and in 2016 to 3.7%, which were both revised down by 0.3% relative to the organization's October 2014 outlook. COMPANY NEWS: Shares of Johnson & Johnson (JNJ) led all decliners on the Dow Jones Industrial Average with a drop of $2.75, or 2.64%, to $101.29 after its Q4 earnings were nearly in-line and its FY15 outlook failed to spur buying of the stock... Morgan Stanley (MS) declined 14c, or 0.4%, to $34.75 after the firm became the latest in the financial space to report headline earnings that missed expectations. MAJOR MOVERS: Among the notable gainers was Smith & Wesson (SWHC), which rose $1.65, or 16.47%, to $11.67 after the gunmaker increased its financial guidance and said it has seen recent, positive trends in the primary indicators it uses to assess its business and the consumer firearm market. Also higher was Orbitz Worldwide (OWW), which jumped 79c, or 8.62%, to $9.95 after Bloomberg reported that the online travel agency is working with an adviser to contact potential buyers and has drawn interest from private-equity funds and "other Internet companies." Among the noteworthy losers was FXCM (FXCM), which plunged $11.03, or 87.33%, to $1.60 after the stock reopened following the company struck a $300M rescue agreement with Leucadia (LUK) and gave further details on that deal over the weekend. Also lower were shares of Redbox owner Outerwall (OUTR), which fell $15.72, or 20.21%, to $62.05 after the company announced that its CEO had stepped down. INDEXES: The Dow rose 3.66, or 0.02%, to 17,515.23, the Nasdaq gained 20.46, or 0.44%, to 4,654.85, and the S&P 500 advanced 3.13, or 0.15%, to 2,022.55.
16:00 EDTJNJOptions Update; January 20, 2015
iPath S&P 500 VIX Short-Term Futures down 36c to 35.12 Option volume leaders: AAPL TSLA TWTR GILD NFLX MGM ABX AMAT JNJ C according to Track Data.
13:08 EDTJNJOn The Fly: Midday Wrap
Subscribe for More Information
11:15 EDTINTCIntel slips after JMP cuts to sell, Canaccord says upgrade not yet warranted
Following Intel's (INTC) fourth quarter results last week, two research firms issued cautious notes on the stock today. JMP Securities downgraded the stock to Underperform, which is the firm's "Sell" equivalent rating, while Canaccord kept a Hold rating on the shares, though the latter firm said its outlook on the company's fundamentals is continuing to become more positive and raised its price target on the name. WHAT'S NEW: Intel's Q4 results were "mixed," but the company's fundamentals appear to have improved, Canaccord analyst Matt Ramsay wrote in a note to investors today. The company's data center group and Internet of Things group should generate sustained 15%+ and 20%+ growth, respectively, over the next several years, the analyst stated. Meanwhile, Intel's PC client group should be able to cut costs further, Ramsay believes. The analyst said he had "intended to upgrade the stock" after the results, given his long-term upbeat view of the company, but was unable to do so. Ramsay explained that he changed his mind because he does not think the company's profits will increase at all this year, while the stock largely already reflects his expectations for solid profit growth in 2016. The analyst increased his price target on the shares to $40 from $36 but kept a Hold rating on the stock. More bearish was JMP Securities analyst Alex Gauna. Gauna downgraded the stock to Underperform from Market Perform and set a $30 price target on Intel. After speaking with a source who sells server components, the analyst reported that the source's business has been weak this month. Weak server component sales are likely to pull down Intel's stock, given its relatively high valuation, the analyst stated. Meanwhile, Intel's gross margins have probably peaked, Gauna believes. PRICE ACTION: In morning trading, Intel fell 1.7% to $35.82.
10:33 EDTJNJJohnson & Johnson falls post-earnings, levels to watch
Subscribe for More Information
09:48 EDTJNJJohnson & Johnson says eyeing options in orthopedics, surgical, vision care
Subscribe for More Information
09:21 EDTJNJJ&J says negative impact of currency to be 'more significant' than expected
Says currency impact will be more significant in 1H than in 2H.
09:20 EDTJNJJ&J says 'comfortable' with models reflecting midpoint of FY EPS view
Subscribe for More Information
09:18 EDTJNJJohnson & Johnson sees FY15 reported sales $75B-$76B
Subscribe for More Information
09:18 EDTJNJJohnson & Johnson CEO says core businesses 'strong'
Johnson & Johnson (JNJ) providing sustainable, high quality healthcare "one of society's greatest challenges." Says core businesses "strong," positioned to continue expanding their leadership positions. CEO Alex Gorsky says company is changing the way it interacts with customers, evolving to be more "effective," "efficient." Says U.S. OTC consent decree requirements completed. Says in the process of developing a China lung center. Says still plans to take $1B out of P&L in next three years. Says aims to bring Ebola vaccine to market "as fast as possible." Says "well-positioned" for long-term. Says currency headwinds have increased "quite substantially," negatively impacting sales, earnings to greater extent than company had anticipated. Sees Depomed (DEPO) transaction closing in Q2. Expects R&D tax credit will be renewed in 2015. If R&D tax credit is approved, sees effective tax rate for 2015 of approx. 20%-21%. Sees operational sales growth for 2015 approx. 6%. Says Wall Street forecasts may not adequately reflect likely negative impact in 2015 of foreign exchange. Sees FY15 operational sales growth 1%-2% in constant currency. Comments made on the Q4 earnings conference call.
08:18 EDTJNJJohnson & Johnson sees 10 major Pharmaceuticals filings from 2013-2017
Sees 10 major filings, 25 line extensions in Pharmaceuticals expected between 2013-2017. Sees about 100 ongoing discovery projects, 50 novel compounds in early development, 5 breakthrough designations. Sees 30 major Medical Devices filings expected from 2014-2016, 20 key Consumer product launches expected global in 2015. Says near-term priorities include: Accelerating growth in Medical Devices through innovation, expanding market leadership in key consumer segments like OTC, Oral Care, Baby and Beauty. Comments from slides that will be presented on the Q4 earnings conference call.
08:07 EDTINTCIntel downgraded at JMP Securities
As noted earlier, JMP Securities downgraded Intel to Underperform from Market Perform. The firm reports that industry sources said there has been a sharp downturn in server activity going into 2015.
07:59 EDTINTCIntel upgrade not warranted due to lack of EPS growth, says Canaccord
Canaccord said it intended to upgrade Intel following its mixed Q4 results, but with estimates for essentially no earnings growth in 2015, the firm could not justify it. As a result, Canaccord raised its price target to $40 from $35 on Intel shares and maintained its Hold rating, but noted it stands ready to upgrade the stock on a pullback.
07:52 EDTJNJJohnson & Johnson reports Q4 Pharmaceutical sales $8B
Subscribe for More Information
07:48 EDTJNJJohnson & Johnson sees FY15 adjusted EPS $6.12-$6.27, consensus $6.13
Subscribe for More Information
07:46 EDTJNJJohnson & Johnson reports Q4 EPS ex-items $1.27, consensus $1.26
Subscribe for More Information
06:12 EDTINTCIntel downgraded to Underperform from Market Perform at JMP Securities
January 16, 2015
16:29 EDTJNJOn The Fly: Closing Wrap
Subscribe for More Information
13:01 EDTJNJEarnings Preview: Johnson & Johnson reports after recent Goldman downgrade
Subscribe for More Information
12:43 EDTJNJOn The Fly: Midday Wrap
Subscribe for More Information
08:58 EDTJNJRoth Capital says Depomed now leading pain company, ups to Buy
Roth Capital upgraded Depomed (DEPO) to Buy from Neutral saying the Nucynta transaction transforms the company into a "leading pain company now with critical mass." Roth raised its price target for shares to $25. Depomed last night announced that it acquired the U.S. rights to the Nucyntafranchise for $1.05B from Johnson & Johnson's (JNJ) Jansen unit. Depomed is trading up 9% in pre-market trading to $19.19.
08:49 EDTINTCIntel CEO says has made 'incremental improvement' on diversity
Subscribe for More Information
08:47 EDTINTCIntel CEO says relationship with Apple 'strong'
Krzanich says he's heard the "rumors" of Apple (AAPL) looking at other types of chips for some of its products. Apple will always choose innovation and Intel's (INTC) job is to offer them the most competitive products, Krzanich said. Intel's CEO says many customers want to have a single supply source, which is a reason Intel needs to be in a broad array of businesses including mobile, PCs and servers. Krzanich says "very comfortable" with inventory levels and that Q4 played out the way the company expected. Intel CEO Brian Krzanich is speaking on CNBC.
08:32 EDTINTCIntel results, 2015 plans 'very impressive,' says Wells Fargo
Subscribe for More Information
08:12 EDTJNJJohnson & Johnson forms Ebola vaccine development consortia
Subscribe for More Information
07:35 EDTINTCChanos says short Intel for around six months
Subscribe for More Information
07:30 EDTINTCIntel post-earnings pullback a buying opportunity, says Jefferies
Subscribe for More Information
07:26 EDTINTCIntel margins to rise through 2015, says Deutsche Bank
Subscribe for More Information
05:59 EDTINTCIntel aims to ship 44M tablet APs in 2015, DigiTimes reports
Intel (INTC) targets shipping 44M tablet APs in 2015 to acount for one third of the non-Apple (AAPL) tablet shipments in 2015, reports DigiTimes. According to sources from tablet players, Intel expects losses from its tablet segment to narrow significant in 2016 as it acquires a leading position in the non-Apple tablet sector. Reference Link
January 15, 2015
18:28 EDTINTCOn The Fly: After Hours Movers
Subscribe for More Information
18:02 EDTINTCIntel says shipped chips into 46M tablets in 2014
Subscribe for More Information
16:42 EDTINTCIntel CFO says corporate PC demand growth likely to slow, consumer to improve
Subscribe for More Information
16:08 EDTINTCIntel down 2% following Q4 results, guidance
Subscribe for More Information
16:08 EDTJNJJ&J unit sells U.S. Nucynta license rights to Depomed for $1.05B
Subscribe for More Information
16:08 EDTJNJDepomed to acquire U.S. rights to NUCYNTA franchise for $1.05B from Jansen
Subscribe for More Information
16:08 EDTINTCIntel sees FY15 revenue growth in mid-single digits, consensus $59.19B
Subscribe for More Information
16:06 EDTINTCIntel CEO says Q4 a 'strong finish to a record year'
Subscribe for More Information
16:05 EDTJNJDepomed to acquire U.S. rights to NUCYNTA franchise for $1.05B from Jansen
16:05 EDTINTCIntel reports Q4 gross margin 65.4%
Subscribe for More Information
16:04 EDTINTCIntel reports Q4 PC Client Group revenue $8.9B, down 3% sequentially, up 3% YoY
Subscribe for More Information
16:02 EDTINTCIntel sees Q1 revenue $13.7B, plus or minus $500M, consensus $13.77B
Subscribe for More Information
16:01 EDTINTCIntel reports Q4 EPS 74c, consensus 66c
Subscribe for More Information
15:14 EDTINTCNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Intel (INTC), consensus 66c; Schlumberger (SLB), consensus $1.46; Bank of the Ozarks (OZRK), consensus 41c; People's United (PBCT), consensus 21c; Wintrust Financial (WTFC), consensus 77c.
15:02 EDTINTCEarnings Preview: Jefferies refutes bear case on Intel
Subscribe for More Information
14:14 EDTINTCIntel technical notes ahead of earnings
The shares have been in a sideways consolidation pattern for the past two months which could become an active, in this case bullish, symmetrical triangle pattern. That pattern would be confirmed and active at or above $37.75. Upside potential for the pattern at a minimum would be to the $40 area. On good news and strong guidance, that pattern could trigger. If the news disappoints, that potential pattern could become void. A move below $36 would destroy the pattern's potential. Next downside levels based on support could be at $35.26, $34.23, and $32.54.
13:29 EDTINTCIntel January 36.5 straddle priced for 3.8% movement into Q4
12:10 EDTJNJJohnson & Johnson volatility elevated into Q4 and outlook
Johnson & Johnson January weekly call option implied volatility is at 22, February is at 16, April is at 15; compared to its 26-week average of 15 according to Track Data, suggesting large movement into the expected release of Q4 results on January 20.
11:20 EDTJNJGoldman cuts J&J to sell citing competitive pressures
Subscribe for More Information
10:00 EDTJNJOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: American Campus (ACC) downgraded to Sell from Neutral at Goldman... Apple (AAPL) downgraded to Neutral from Buy at Mizuho... Archer Daniels (ADM) downgraded to Neutral from Buy at Goldman... Barrick Gold (ABX) downgraded to Underweight from Equal Weight at Barclays... CNOOC (CEO) downgraded to Underperform from Hold at Jefferies... CSC (CSC) downgraded to Underweight from Neutral at JPMorgan... Computer Programs (CPSI) downgraded to Market Perform from Outperform at William Blair... D.R. Horton (DHI) downgraded to Neutral from Buy at UBS... DDR Corp. (DDR) downgraded to Neutral from Overweight at JPMorgan... Dominion Diamond (DDC) downgraded to Equal Weight from Overweight at Barclays... EVERTEC (EVTC) downgraded to Neutral from Overweight at JPMorgan... Education Realty (EDR) downgraded to Sell from Neutral at Goldman... Franco-Nevada (FNV) downgraded to Underweight from Equal Weight at Barclays... General Cable (BGC) downgraded to Neutral from Buy at Longbow... Green Dot (GDOT) downgraded to Neutral from Overweight at JPMorgan... Greif (GEF) downgraded to Neutral from Buy at BofA/Merrill... Grupo Simec (SIM) downgraded to Neutral from Buy at Goldman... Hecla Mining (HL) downgraded to Hold from Buy at BB&T... Host Hotels (HST) downgraded to Hold from Buy at MLV & Co.... Ingredion (INGR) downgraded to Sell from Neutral at Goldman... Insulet (PODD) downgraded to Market Perform from Outperform at Raymond James... Johnson & Johnson (JNJ) downgraded to Sell from Neutral at Goldman... Magna (MGA) downgraded to Hold from Buy at TD Securities... Molson Coors (TAP) downgraded to Neutral from Buy at Goldman... Nuverra Environmental (NES) downgraded at Roth Capital... Omnicom (OMC) downgraded to Hold from Buy at Evercore ISI... PetroChina (PTR) downgraded to Underperform from Hold at Jefferies... Philip Morris (PM) downgraded to Sell from Neutral at Goldman... Precision Castparts (PCP) downgraded to Hold from Buy at KeyBanc... Rio Tinto (RIO) downgraded to Neutral from Outperform at Macquarie... STAG Industrial (STAG) downgraded to Neutral from Overweight at JPMorgan... Silicon Laboratories (SLAB) downgraded to Equal Weight from Overweight at Barclays... Sinopec (SNP) downgraded to Underperform from Hold at Jefferies... Sky (SKYAY) downgraded to Neutral from Outperform at Exane BNP Paribas... Teledyne (TDY) downgraded to Underweight from Hold at KeyBanc... Woodward (WWD) downgraded to Underweight from Hold at KeyBanc... Xilinx (XLNX) downgraded to Equal Weight from Overweight at Barclays.
07:06 EDTJNJJohnson & Johnson downgraded at Goldman
Subscribe for More Information
06:44 EDTJNJJohnson & Johnson downgraded to Sell from Neutral at Goldman
06:27 EDTINTCIntel to partner with more IT players for Internet of Things, DigiTimes reports
Intel (INTC) is preparing to team up with more IT firms such as AT&T (T), Verizon (VZ), Cisco (CSCO), SAP (SAP), and Microsoft (MSFT) in order to expand the Internet of Things industry in 2015, reports DigiTimes. According to sources from the upstream supply chain, Intel has been playing an active role in helping Taiwan build its smart city infrastructure and has also cooperated with Chunghwa Telecom to develop the IoT and cloud computing applications. Reference Link
<< 1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use